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Chemotherapy is an important part of treatment of cancer. Currently, the use of 
several anticancer drugs in combination seem to be more advantageous. This combination 
therapy prevents drug resistance development and make it possible to lower the doses of 
single drugs, which prevents the side effects in non-cancerous tissues. Large pool of 
potential drugs for combination therapy can be found among natural compounds, for 
example among sesquiterpenes. 
Our project was designed to evaluate the effect of Myrica rubra essential oil 
(MEO) and selected sesquiterpenes in combination cancer therapy. We focused on the 
potential ability of MEO and sesquiterpenes to increase the antiproliferative efficacy of 
classical cytostatics (doxorubicin, oxaliplatin, 5-fluorouracil). In addition, we also studied 
the possible interaction of sesquiterpenes with other drugs in combination therapy, which 
could be caused by sesquiterpene-mediated modulation of drug-metabolizing enzymes. 
For these purposes, a panel of various cell lines (both cancerous and non-cancerous) and 
primary culture of hepatocytes were used in in vitro experiments. Normal and tumor 
bearing mice were chosen as in vivo models. 
MEO has significant antiproliferative effect in intestine cancer cell lines HTC-8, 
HT-29, SW480, SW620 and Caco-2. MEO was able to potentiate efficacy of DOX 
in cancer cells. Increase of efficacy correlated with enhanced intracellular DOX 
concentration and increased production of ROS. MEO has no effect on viability, 
intracellular DOX concentration and ROS production in primary culture of hepatocytes. 
Sesquiterpenes β-caryophyllene (CAR), β-caryophyllene oxide (CAO), α-humulene 
(HUM), trans-nerolidol (NER) and valencene (VAL) are main components of MEO. 
Their antiproliferative effects were tested in cancer cell lines, when they were used alone 
and in combination with selected cytostatics DOX, 5-fluorouracil, oxaliplatin. All 
 
sesquiterpenes (except CAR) were able to increase DOX efficacy in Caco-2 cell line. 
Viability of hepatocytes was not affected by sesquiterpenes. Antiproliferative activity of 
OxPt and FU was increased, dominantly by CAO. In the next study, ovarian cancer cell 
lines with different sensitivity and two lymphoblast cancer cell lines, one sensitive and 
the other DOX completely resistant (with overexpression of ABCB1 transporter) were 
used. Sesquiterpenes were able to increase efficacy of DOX in all cell lines with exception 
of DOX resistant cell line. Nevertheless, sesquiterpenes were able to increase intracellular 
DOX concentration and to inhibit ABCB1 transporter in DOX-resistant cell line. In vivo, 
the use of sesquiterpenes in combination with DOX led to neither increase of DOX 
concentration in tumors nor size of tumors in tumor bearing mice. 
In vitro study of potential inhibitory effect of sesquiterpenes on drug-metabolizing 
enzymes showed significant ability of sesquiterpenes to inhibit cytochrome P450 (CYP). 
Activities of carbonyl reducing enzymes and conjugating enzymes were not inhibited by 
sesquiterpenes. On the other hand, CAO and NER in vivo increased activities and 
expression of CYP2B, 3A and 2C in mouse liver and small intestine. In liver, elevated 
activity of aldo-ketoreductase 1C, carbonyl reductase and sulpfhotransferase were also 
found. Contrary, sesquiterpenes decreased NAD(P)H:quinone oxidoreductase 1 activity 
in small intestine.  
Results from this doctoral thesis show possible beneficial effects of sesquiterpenes 
in cancer treatment. However, it is necessary to take into mind their ability to modulate 
activity of drug-metabolizing enzymes and possibility of sesquiterpene-drug interactions. 
  
